Mayo Clinic researchers find that stem cells with the highest Myc expression become dominant in driving lung remodeling .

But many existing models fall short of adhering to established best practices for economic evaluation, the review authors found. Another challenge: Existing models may not be well-suited for evaluating personalized treatments.

A prediction for 2025 from Laura Kohlhagen, M.D., MBA, chief medical officer, of Altera Digital Health.

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer Society's annual report on cancer incidence and mortality. But there is a wide gap between how well White patients fare compared to Black patients.

Ozempic, Rybelsus and Wegovy top the list of the newest drugs selected for Medicare Part D price negotiation, part of the Inflation Reduction Act.

Cancer mortality rates have decreased by 34% overall, but incidence rates for women of all ages continue to rise, according to a new report from the American Cancer Society.

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the intestinal tract, when compared to placebo.

Berge will serve in this role through the end of 2026, marking another milestone in her successful career in healthcare.

Luke Twelves, M.D., vice president of Medical for Lindus Health, shared his prediction for the year.

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on?

Lyle Berkowitz, M.D., CEO of KeyCare, gives a prediction for 2025.

A prediction for 2025 by George Pappas, CEO of Intraprise Health.

In an investor call, Andrew Witty promised full transparency and 100% pass-through rebates for prescription drugs by 2028.

The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

UnitedHealth Group reported a medical care ratio in 2024 of 85.5% compared with 83.2% in 2023.

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age after October 25 received maternal RSVpreF.

A prediction for the year by Brandi Meyers, vice president of Revenue Operations at MDClone.

A South Korean study explored the link between lifestyle decisions beginning in infancy and persistent atopic dermatitis, citing exclusive breast milk diet and childhood obesity as potential factors.

Kim Perry, chief growth officer of Emtelligent, shares her prediction for 2025.

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells invisible to a patient’s immune system.

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The FDA has set a goal date of Aug. 31, 2025.

Study authors Susan D. Reed, MD, MPH, MS, and Erin Dwyer, MPH, both at the University of Washington School of Medicine, attribute some of these different challenges to underlying health disparities.

A prediction of 2025 by Doug Mirsky, Ph.D., vice president of healthcare delivery at Digital Medicine Society.

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and steer patients to their own pharmacies.

A prediction for this year by Shawn Gremminger, president and CEO of National Alliance of Healthcare Purchaser Coalitions.